Category: AT-527
Shots: The P-II MOONSONG trial evaluates the antiviral activity, safety & PK of AT-527 (550/1100 mg, bid) vs PBO in adult patients with COVID-19. The therapy is jointly developed in collaboration with Roche The trial did not meet its 1EPs of reduction from baseline in SARS-CoV-2 virus in an overall study population, two-thirds of patients […]
Shots: Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company believes that AT-527 is suitable for use in both pre-and post-exposure prophylactic settings and complementary to vaccines The companies are jointly developing AT-527 for the […]
Shots: The P-I study involves assessing the safety and PK of AT-527 (550 mg, q2, BID) vs PBO for 5 days in 20 healthy volunteers in a ratio (1:1) to treat COVID-19 The result showed rapid attainment of steady state levels within 2days of dosing, predicted lung AT-9010 levels were consistently above the EC90 level […]
Shots: Chugai gets exclusive development and commercializing rights for AT-527 in Japan Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in […]
Shots: The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US The therapy is currently being evaluated in P-II study for […]